Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., announced its strategic vision to expand its biosimilar oncology portfolio by introducing three new oncology biosimilars: proposed biosimilars for Trastuzumab/Hyaluronidase combination, Nivolumab, and Pembrolizumab. These new assets, including two PD-1 inhibitors, will contribute to Biocon Biologics having one of the most comprehensive oncology portfolios in the industry, addressing an estimated over $75 billion opportunity. The company also revealed plans to integrate as a wholly owned subsidiary of Biocon Limited, a process expected to be completed no later than March 31, 2026. This integration aims to leverage global commercial infrastructure, simplify the corporate structure, and strengthen Biocon's global leadership in biosimilar insulins and GLP-1 peptide generics, positioning it as the only company offering both. Shreehas Tambe, CEO & Managing Director of Biocon Biologics, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. He is scheduled to present on Thursday, January 15, 2026, at 8:00 AM PST / 11 AM EST / 9:30 PM IST. Additionally, he will participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13, 2026. The integration is expected to enhance Biocon Biologics' ability to deliver innovative, affordable medicines to over 6 million patients in more than 120 markets worldwide. Post-integration, Shreehas Tambe will assume the role of CEO & Managing Director of the combined business.
